These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
479 related articles for article (PubMed ID: 24702306)
1. The prevalence of co-prescription of clinically relevant CYP enzyme inhibitor and substrate drugs in community-dwelling elderly Australians. Kerr KP; Mate KE; Magin PJ; Marley J; Stocks NP; Disler P; Pond CD J Clin Pharm Ther; 2014 Aug; 39(4):383-9. PubMed ID: 24702306 [TBL] [Abstract][Full Text] [Related]
2. Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors. Molden E; Skovlund E; Braathen P Drug Saf; 2008; 31(7):587-96. PubMed ID: 18558792 [TBL] [Abstract][Full Text] [Related]
3. Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population. Bakhai A; Rigney U; Hollis S; Emmas C Pharmacoepidemiol Drug Saf; 2012 May; 21(5):485-93. PubMed ID: 22237927 [TBL] [Abstract][Full Text] [Related]
4. Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy. Doan J; Zakrzewski-Jakubiak H; Roy J; Turgeon J; Tannenbaum C Ann Pharmacother; 2013 Mar; 47(3):324-32. PubMed ID: 23482734 [TBL] [Abstract][Full Text] [Related]
5. Potentially inappropriate prescribing to hospitalised patients. Radosević N; Gantumur M; Vlahović-Palcevski V Pharmacoepidemiol Drug Saf; 2008 Jul; 17(7):733-7. PubMed ID: 18050360 [TBL] [Abstract][Full Text] [Related]
6. Prescribing patterns and predictors of high-level polypharmacy in the elderly population: A prospective surveillance study from two teaching hospitals in India. Harugeri A; Joseph J; Parthasarathi G; Ramesh M; Guido S Am J Geriatr Pharmacother; 2010 Jun; 8(3):271-80. PubMed ID: 20624616 [TBL] [Abstract][Full Text] [Related]
7. Co-prescription of cytochrome P450 2D6/3A4 inhibitor-substrate pairs in clinical practice. A retrospective analysis of data from Norwegian primary pharmacies. Molden E; Garcia BH; Braathen P; Eggen AE Eur J Clin Pharmacol; 2005 Apr; 61(2):119-25. PubMed ID: 15692832 [TBL] [Abstract][Full Text] [Related]
8. Assessment of Anti-Xa activity in patients receiving concomitant apixaban with strong p-glycoprotein inhibitors and statins. Milner E; Ainsworth M; Gleaton M; Bookstaver D J Clin Pharm Ther; 2022 May; 47(5):668-675. PubMed ID: 35032137 [TBL] [Abstract][Full Text] [Related]
9. Prevalence of the prescribing of potentially inappropriate medications at ambulatory care visits by elderly patients covered by the Taiwanese National Health Insurance program. Lai HY; Hwang SJ; Chen YC; Chen TJ; Lin MH; Chen LK Clin Ther; 2009 Aug; 31(8):1859-70. PubMed ID: 19808145 [TBL] [Abstract][Full Text] [Related]
10. Prevalence of Potential and Clinically Relevant Statin-Drug Interactions in Frail and Robust Older Inpatients. Thai M; Hilmer S; Pearson SA; Reeve E; Gnjidic D Drugs Aging; 2015 Oct; 32(10):849-56. PubMed ID: 26442861 [TBL] [Abstract][Full Text] [Related]
11. [Risk of pharmacological interactions due to the co-administration of statins and cytochrome P450 isoenzyme 3A4-metabolized drugs: multicentre, crossover study]. Mostaza JM; Lahoz C; Morales-Olivas F; Pinto X; Tranche S; Suarez-Tembra M; Mantilla T; Rius J Med Clin (Barc); 2014 Nov; 143(10):427-32. PubMed ID: 24216013 [TBL] [Abstract][Full Text] [Related]
12. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. Neuvonen PJ Curr Opin Investig Drugs; 2010 Mar; 11(3):323-32. PubMed ID: 20178046 [TBL] [Abstract][Full Text] [Related]
13. Avoiding patient morbidity: Updated statin drug interactions and risks for patient harm. Finks SW; Campbell JD Nurse Pract; 2014 Nov; 39(11):45-51. PubMed ID: 25325525 [TBL] [Abstract][Full Text] [Related]
14. Frequency and clinical relevance of drug interactions with lovastatin and simvastatin: an observational database study. Tirkkonen T; Ryynänen A; Vahlberg T; Irjala K; Klaukka T; Huupponen R; Laine K Drug Saf; 2008; 31(3):231-40. PubMed ID: 18302447 [TBL] [Abstract][Full Text] [Related]
15. [Concomitant use of statins and cytochrome P 450 inhibitors in Croatia]. Reiner Z; Galić M; Hanzevacki M; Tedeschi-Reiner E Lijec Vjesn; 2005; 127(3-4):65-8. PubMed ID: 16193855 [TBL] [Abstract][Full Text] [Related]
16. Impact of multiple inhibitors or substrates of cytochrome P450 2D6 on plasma risperidone levels in patients on polypharmacy. Mannheimer B; von Bahr C; Pettersson H; Eliasson E Ther Drug Monit; 2008 Oct; 30(5):565-9. PubMed ID: 18728628 [TBL] [Abstract][Full Text] [Related]
17. Role of P-glycoprotein in statin drug interactions. Holtzman CW; Wiggins BS; Spinler SA Pharmacotherapy; 2006 Nov; 26(11):1601-7. PubMed ID: 17064205 [TBL] [Abstract][Full Text] [Related]
18. Prevalence and predictors of anticholinergic agents in elderly outpatients with dementia. Bhattacharya R; Chatterjee S; Carnahan RM; Aparasu RR Am J Geriatr Pharmacother; 2011 Dec; 9(6):434-41. PubMed ID: 22030114 [TBL] [Abstract][Full Text] [Related]
19. Physical Performance and Quality of Life in Older Adults: Is There Any Association between Them and Potential Drug Interactions in Polymedicated Octogenarians. Verde Z; García de Diego L; Chicharro LM; Bandrés F; Velasco V; Mingo T; Fernández-Araque A Int J Environ Res Public Health; 2019 Oct; 16(21):. PubMed ID: 31671923 [TBL] [Abstract][Full Text] [Related]
20. Review of prescription medications in home-based older adults with stroke: a pilot study. Classen S; Meuleman J; Garvan C; Ried LD; Mann W; Asal N Res Social Adm Pharm; 2007 Mar; 3(1):104-22. PubMed ID: 17350560 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]